PRA narrows its sales guidance on the way to a record year

PRA Health Sciences posted another quarter of revenue growth but is narrowing its full-year sales projection.

Charles River boosts its 2015 outlook after strong sales quarter

Charles River Laboratories returned to revenue growth on a wave of dealmaking, lifting its full-year guidance in response.

WuXi pads its revenue on the way to a big buyout decision

Chinese CRO WuXi PharmaTech extended its run of quarterly growth on the eve of a shareholder vote that could take the company private in a multibillion-dollar deal.

Novartis, Qualcomm back trial startup's $6.5M round

Lux Ventures and a joint venture between Novartis and Qualcomm are investing $6.5 million into Science 37, an upstart company that promises to make clinical trials more efficient by uniting stakeholders.

Parexel's profits slide as it slashes costs

Parexel International, in the process of shedding about 850 jobs, saw its net income dip in the fiscal first quarter, dimming its expectations for the full year.

INC boosts its outlook after another big revenue quarter

INC Research is ticking up its revenue expectations for 2015 after turning in another quarter of sales growth, counting on its expanded operation to keep contracts rolling in.

Icon ekes out another quarter of growth despite currency woes

Irish-headquartered CRO Icon kept its streak of quarterly revenue growth running, posting a 1.8% year-over-year increase in sales.

PRA upgrades its Dutch R&D hub with eyes on bioanalytics

CRO PRA Health Sciences upsized one of its European outposts, investing in bioanalytical services to bolster its clinical research operations in the region.

Quintiles narrows its outlook after another positive quarter

CRO giant Quintiles posted another $1 billion revenue quarter on the way to a record year, but the company is narrowing its sales projections over ongoing foreign exchange issues.

BioClinica revamps its CRO partner program

BioClinica is changing how it does business with other CROs, the company said, responding to client demand and rolling out a new partnering program.

SRI inks a $100M contract with NIH to study treatments for radiation exposure

SRI International's CRO division signed a deal with the National Institutes of Health that could bring in up to $100 million over 5 years, agreeing to help develop therapies designed to treat the effects of radiation exposure.

Post-IPO Syngene posts 28% quarterly revenue growth

India's Syngene, the recently IPO'd CRO division of Biocon, kept up its years-long run of growth with a 28% revenue boost in the second quarter of its fiscal year.

Quintiles pairs up with IMS to use real-world data in post-market studies

Quintiles signed a deal with healthcare information giant IMS Health to pair its own clinical development expertise with its partner's huge trove of real-world data, planning to use anonymized patient information to steer drug trials.

Quintiles shuffles its C-suite with new CFO, COO

Quintiles, the world's largest CRO, is promoting a new chief operating officer from within and bringing on an external chief financial officer as the company rolls toward a record revenue year.

Evotec partners up for rare disease R&D in a discovery deal

Evotec's CRO division signed a deal with the Beyond Batten Disease Foundation to help discover new potential treatments for the rare, fatal nervous disorder.

PRA adds a biotech vet to its board amid an expansion effort

PRA Health Sciences added biotech veteran Linda Grais to its board of directors, broadening its managerial suite as it works to grow around the globe.

CRO Frontage gets into agrochemicals with new service offering

Contract drug developer Frontage Laboratories is expanding its business to include agrochemical testing, adding capacity in hopes of lengthening its client roster.

Cel-Sci lines up cash to fund its $50M suit against ex-partner inVentiv

Cel-Sci, at work on a Phase III cancer treatment, has signed up to borrow up to $5 million as it pursues a $50 million lawsuit against former CRO partner inVentiv Health.

Aesica bids to manage its clients' many contractors

Contract drug developer Aesica wants to become its clients' sole point of contact among their many vendors, pitching an all-encompassing service offering.

INC bolsters its Phase I platform with new cardiac tech

INC Research added a new tool for early-stage safety studies, bringing in a new technology the company says will make Phase I cardiac trials more efficient.